Articles related to LIPID MANAGEMENT

Lerochol (lerodalcibep-liga), a once-monthly self-administered PCSK9 inhibitor, is now commercially available as adjunctive LDL-C-lowering therapy for adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.

Prenatal exposure to medications that inhibit sterol biosynthesis was associated with higher rates of autism spectrum disorder diagnosis in a 6.14-million-record retrospective analysis.

ACC/AHA’s 2026 dyslipidemia guideline reintroduces LDL-C and non-HDL-C treatment goals, replaces Pooled Cohort Equations with PREVENT, and recommends one-time lipoprotein(a) measurement in all adults.

Extreme LDL-C in young patients with family history points toward familial hypercholesterolemia, a common genetic disorder that remains undiagnosed in 70% of cases.

Rare lipid disorders can drive extreme cholesterol abnormalities and early disease, making clinical recognition critical when lipid patterns don’t fit typical cardiology presentations.

According to the Gould Registry, in 5,006 patients with ASCVD, only one in three patients had LDL cholesterol even less than 70mg/dl.